Kilitch Drugs (India) Limited (KILITCH) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Kilitch Drugs (India) Limited ₹140, price ₹219, upside -36.0%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Kilitch Drugs (India) Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹63.33 – ₹243.93 · fair‑value band ₹102.95 – ₹179.86 · the ₹218.51 price screens above the ₹139.77 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Kilitch Drugs (India) in your weekly email
Every Wednesday you see whether Kilitch Drugs (India) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally.
Show more
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Stock analysis
Kilitch Drugs (India) Limited (KILITCH) currently trades at ₹218.51, while our model-based Fair Value estimate is ₹139.77, 36.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹233.56 per share, and 2 of the 14 models we run sit above the ₹218.51 price.
Bear case: the Economic Profit group reads lowest at ₹42.55, and 12 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹102.95 (bear) to ₹179.86 (bull), the price of ₹218.51 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Kilitch Drugs (India) Limited reported revenue of ₹2.4B in FY2026 versus ₹1.1B in FY2022, a compound +19.8%/yr. Reported net income was ₹302M in FY2026, compounding +42.3%/yr from FY2022.
Key figures
Market cap ₹7.4B (≈ $76.8M) · P/E ratio 24.5 · P/S ratio 3.14 · EPS (TTM) ₹8.92 · Net margin 12.8% · Return on equity 12.4% · Return on assets (EBIT) 7.2% · Operating margin 23.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 76% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −36%, KILITCH screens richer than that median.
Fair Value models
Bear ₹102.95Fair Value ₹139.77Bull ₹179.86
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹4.52 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+18.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.2%
Start year 2021 (pandemic). Over 10 years: +27.4% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+49.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+49.7%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 14%
2026 sits 94% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare Kilitch Drugs (India) Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−36.0% · Below median
Profitability
Return on equity (TTM)12.4% · Above median
Return on assets5.4% · Above median
Net margin (TTM)12.8% · Above median
Operating margin (TTM)23.6% · Top 25%
Growth and dividend
Revenue growth46.3% · Top 25%
Balance sheet
Debt / equity0.21× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)24.5× · Pricier than median
P/B2.65× · Pricier than median
P/S (TTM)3.14× · Pricier than median
EV/EBITDA21.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 24
PAST (return on equity)49· sector 28
HEALTH (low debt)90· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Kilitch Drugs (India) Limited (KILITCH) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹139.77 versus a price of ₹218.51, about −36% upside (overvalued).
What is the fair value of KILITCH?
Our model-based fair value for Kilitch Drugs (India) Limited is ₹139.77 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹218.51.
What is the quality score of KILITCH?
Kilitch Drugs (India) Limited has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kilitch Drugs (India) Limited (KILITCH)?
Our model-based price target is the fair value of ₹139.77 (as of Sep 27, 2026) from 14 valuation models. Cautious scenario ₹102.95, optimistic scenario ₹179.86. It is a calculation from audited fundamentals, not an analyst target.
What is the Kilitch Drugs (India) Limited stock forecast for 2026?
Our models put fair value at ₹139.77, about −36% upside versus a price of ₹218.51 (overvalued). Cautious scenario ₹102.95, optimistic scenario ₹179.86. The calculation is refreshed regularly with new filings.
What is the revenue of Kilitch Drugs (India) Limited (KILITCH)?
Kilitch Drugs (India) Limited reported trailing-twelve-month revenue of about ₹2.4B (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Kilitch Drugs (India) Limited (KILITCH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kilitch Drugs (India) Limited it is ₹139.77 per share (as of Sep 27, 2026), against a price of ₹218.51. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Kilitch Drugs (India) Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, KILITCH trades above its calculated fair value: price ₹218.51, fair value ₹139.77, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KILITCH?
No. The price is what the market pays today (₹218.51); the fair value is what the company's own numbers justify (₹139.77). For Kilitch Drugs (India) Limited the two are ₹78.74 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kilitch Drugs (India) Limited worth?
The market values Kilitch Drugs (India) Limited at about ₹7.4B (market capitalisation, as of Sep 27, 2026). Per share that is ₹218.51; our models calculate a fair value of ₹139.77 per share.
What do the bullish and bearish scenarios say about KILITCH?
Our models span a range for Kilitch Drugs (India) Limited: cautious scenario ₹102.95, base ₹139.77, optimistic ₹179.86 per share (as of Sep 27, 2026, price ₹218.51). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KILITCH?
Kilitch Drugs (India) Limited trades at a price-to-earnings ratio of 24.5 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹139.77 is built from several models across several years. Other multiples: P/B 2.7, P/S 3.1, EV/EBITDA 21.4.
How solid is the balance sheet of Kilitch Drugs (India) Limited (KILITCH)?
Balance-sheet figures for Kilitch Drugs (India) Limited (as of Sep 27, 2026): return on equity 12.4%, debt of 0.21 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is KILITCH from its 52-week high?
Kilitch Drugs (India) Limited trades at ₹218.51, about 3% below its 52-week high of ₹224.27 and 76% above the low of ₹124.45 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹139.77 is for.
Which stocks are comparable to Kilitch Drugs (India) Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kilitch Drugs (India) Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹218.51, calculated fair value ₹139.77 (−36%), Quality Score 32/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KILITCH calculated?
We run Kilitch Drugs (India) Limited through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹139.77, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Kilitch Drugs (India) Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kilitch Drugs (India) Limited (KILITCH)?
The closing price on Oct 1, 2026 was ₹218.51. Our model-based fair value is ₹139.77, about −36% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kilitch Drugs (India) Limited right now?
The price sits above even our optimistic bull case (₹179.86). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Kilitch Drugs (India) Limited
How large is the market capitalisation of Kilitch Drugs (India) Limited (KILITCH)?
The market capitalisation of Kilitch Drugs (India) Limited is ₹7.4B (≈ $76.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kilitch Drugs (India) Limited (KILITCH)?
The price-to-sales ratio of Kilitch Drugs (India) Limited is 3.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kilitch Drugs (India) Limited (KILITCH)?
Earnings per share at Kilitch Drugs (India) Limited are ₹8.92 (price ÷ EPS = P/E 24.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Kilitch Drugs (India) Limited (KILITCH)?
The net margin of Kilitch Drugs (India) Limited is 12.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kilitch Drugs (India) Limited (KILITCH)?
The return on equity (ROE) of Kilitch Drugs (India) Limited is 12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kilitch Drugs (India) Limited (KILITCH)?
On an EBIT basis the return on assets of Kilitch Drugs (India) Limited is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kilitch Drugs (India) Limited (KILITCH)?
The operating margin of Kilitch Drugs (India) Limited is 23.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kilitch Drugs (India) Limited (KILITCH)?
Revenue at Kilitch Drugs (India) Limited is growing +46.3% versus a year earlier (3y avg +19.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kilitch Drugs (India) Limited (KILITCH)?
Earnings per share at Kilitch Drugs (India) Limited are growing +26.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Kilitch Drugs (India) Limited (KILITCH) generate?
The free cash flow of Kilitch Drugs (India) Limited is −₹806M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kilitch Drugs (India) Limited (KILITCH) carry?
The net debt of Kilitch Drugs (India) Limited is ₹719M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kilitch Drugs (India) Limited in the live analysis
One click puts Kilitch Drugs (India) Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
